# Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma

> **NCT03767725** · PHASE1 · UNKNOWN · sponsor: **Shenzhen Second People's Hospital** · enrollment: 10 (estimated)

## Conditions studied

- Multiple Myeloma in Relapse

## Interventions

- **BIOLOGICAL:** Treatment

## Key facts

- **NCT ID:** NCT03767725
- **Lead sponsor:** Shenzhen Second People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2018-06-02
- **Primary completion:** 2021-06-01
- **Final completion:** 2021-09-01
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2018-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03767725

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03767725, "Anti-BCMA or/and Anti-CD19 CART Cells Treatment of Relapsed Multiple Myeloma". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT03767725. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*